Mammographic density is a strong risk factor for first primary breast cancer, but its role in the development of a second breast cancer in the opposite (contralateral) breast is not known. The WECARE Study is collecting mammograms to measure mammographic density and evaluate its role in the development of a new cancer in the contralateral breast. It has previously been shown that mammographic density is altered in response to some hormonal and other treatments. Therefore, the study will investigate the combined effects of treatment for the first breast cancer and mammographic density. If mammographic density is found to be a useful marker of risk, it could help identify women at high risk of contralateral breast cancer, an important issue for the many women who survive their first breast cancer.
Esther M. John, Ph.D. (Principal Investigator)
Jonine Bernstein, Ph.D. (Principal Investigator) (Memorial Sloan-Kettering Cancer Center), Kathleen Malone, Ph.D. (Fred Hutchinson Cancer Research Center), Charles Lynch, Ph.D. (University of Iowa), Julia Knight, Ph.D. (Mount Sinai Hospital, New York)
National Cancer Institute